Condition
Diabetes Mellitus, Type 2
Locations
Germany
Start date
22/10/2026
Identifiers
Trial ID NN9836-8513,
NCT number NCT07896109,
Eudract number Not Available
NCT number NCT07896109,
Eudract number Not Available
Summary
The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or placebo. Which treatment participants get is decided by chance. NNC9836-0001 is a new medicine aimed to treat type 2 diabetes.
Trial Overview:
Treatment
DRUG: NNC9836-0001
DRUG: Placebo (NaCl)
Study type
INTERVENTIONAL
Trial duration
Oct 22 2026 - Jul 26 2028
Participants
121
Phase
I
Are you eligible?
Gender
Male and female
Age
25 to 69 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.